乳腺癌血清VEGF水平与癌组织中VEGF和COX-2表达及微血管密度的关系

Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues

目的探讨乳腺癌患者血清血管内皮生长因子(sVEGF)水平与乳腺癌血管生成的关系。方法采用酶联免疫吸附试验(ELISA)检测68例乳腺癌、35例乳腺良性病变和20例健康女性的sVEGF水平,免疫组化S-P法检测相应乳腺癌组织中VEGF、环氧合酶-2(COX-2)及微血管密度(MVD)表达水平,并分析sVEGF水平与VEGF、COX-2及MVD表达的关系。结果(1)健康女性组、乳腺良性病变组和乳腺癌组sVEGF浓度中位数分别为105.93、150.82和306.51 pg/ml,乳腺癌组明显高于健康女性组。(2)乳腺癌组VEGF和COX-2表达阳性率分别为67.6%和44.1%,乳腺良性病变组VEGF和COX-2表达阳性率分别为42.9%和11.4%,两组间差异有统计学意义(P值分别为0.015和0.002)。(3)乳腺癌患者sVEGF水平与癌组织中VEGF、COX-2及MVD表达均呈正相关。(4)乳腺癌患者中,VEGF表达阳性组COX-2阳性率(65.21%)明显高于VEGF表达阴性组(18.18%); COX-2表达阳性组MVD(22.94±5.51)明显高于COX-2表达阴性组(10.30±4.42)。结论乳腺癌患者sVEGF水平明显增高于健康女性,并与癌组织中VEGF、COX-2及MVD表达呈正相关。

Objective To investigate the relationship between serum VEGF （sVEGF） level and VEGF, COX-2 and MVD expression in breast cancer, and to discuss their role in angiogensis of breast cancer. Methods sVEGF level was detected by ELISA in 68 preoperative breast cancer, 35 benign breast disease and 20 healthy women. The expression of VEGF, COX-2 and MVD was detected by method in tissues of breast cancer and breast benign diseases, and to analyze the relationship of sVEGF, VEGF, COX-2 and MVD. Results （1） sVEGF level in preoperative breast cancers was 306.51 pg/ml （ interquaxtile range from 190. 44 to 442.04 pg/ml ）, in benign diseases was 150.82 pg/ml （ interquartile range from 82.36 to 212.34 pg/ml） ,and in healthy control was 105.93 pg/ml （interquartile range from 78.54 to 157.77 pg/ml）. The sVEGF level of preoperative breast cancer group was significantly higher than that of breast benign disease group and healthy women （P = 0.001 ）. （2） The VEGF expression positive rate in breast cancer （67.65%） was significantly higher than that in breast benign disease （44.12%） （P =0. 015）. The COX-2 expression positive rate in breast cancer （42.86%） was significantly higher than that in breast benign disease （ 11.43% ） （ P = 0.002 ）. （ 3 ） the COX-2 expression positive rate in sVEGF high level patients （ 56.00% ） was significantly higher than that in sVEGF normal level patients （ 11.11% ） （ P = 0.024 ）, and MVD in sVEGF high level patients （ 27.32 ± 3.40 ） was also higher than that in sVEGF normal level patients （ 15.31 ± 6. 16 ） （ P = 0. 011 ）. （4） The sVEGF level （322.09 ± 79.31 ） of 68 breast cancer patients whose VEGF was positive in breast cancer tissues was significantly higher than that in VEGF negative group （222.47 ± 73.53 ） （ P = 0. 017 ）. （ 5 ） The COX-2 expression positive rate in VEGF positive expression group （65.21%） was significantly higher than that in VEGF negative expression group （ 18. 18% ） （ P = 0. 017 ）. The MVD expression in COX-2 positive expression group （22.94 ± 5.51 ） was significantly higher than that in COX-2 negative expression group （ 10.30 ± 4.42） （P = 0. 027）. Conclusion sVEGF level in breast cancer is significantly higher than that in breast benign disease and healthy women, and is correlated with the expression of COX-2 and MVD in breast cancer tissues.